Mountainfield Venture Partners and Chengdu, China-based Keymed Biosciences Co. Ltd have partnered to form San Diego-based Timberlyne Therapeutics, which will progress Keymed’s CD-38 monoclonal antibody globally excluding China.
Shares of Phio Pharmaceuticals Corp. soared 291% Jan. 13 on news that two patients with cutaneous squamous cell carcinoma had a complete response following treatment with the company’s Intasyl siRNA gene silencing candidate PH-762.
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. The two have agreed to develop SIM-0500, a humanized GPRC5D-BCMA-CD3 trispecific antibody, which is in phase I studies in the U.S. and China to treat refractory multiple myeloma.
Joining the dealmaking spree to kick off the 2025 J.P. Morgan Healthcare Conference, Eli Lilly and Co. announced it was picking up an early clinical-stage PI3Kα inhibitor program from Scorpion Therapeutics Inc. in a deal that could be worth up to $2.5 billion, while GSK plc is adding to its cancer pipeline with the acquisition of Idrx Inc. for $1 billion up front.
Centre National de la Recherche Scientifique (CNRS) and Université Grenoble Alpes have developed new iridium complexes acting as photosensitizers for photodynamic therapy and reported to be potentially useful for the treatment of cancer.
Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers retaining wild-type p53.
Researchers from Boehringer Ingelheim Pharma GmbH & Co KG have published preclinical data for their novel pan-KRAS inhibitors BI-2493 and BI-2865, both being developed for the treatment of cancer. Previous research has shown that these pan-KRAS inhibitors target KRAS in the inactive OFF state, while sparing HRAS and NRAS.
An exclusive licensing agreement with Insilico Medicine Inc. grants Menarini’s Stemline Therapeutics Inc. the global rights to develop and commercialize a preclinical small molecule for high unmet needs in oncology.
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYS-6041, an antibody-drug conjugate, for advanced solid tumors.
RSS
